Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Expression of the MN1–TEL fusion protein in the human UCSD/AML1 leukemic cell line

Leukemia volume 18, pages 1558–1560 (2004)Cite this article

TO THE EDITOR

The TEL gene (also known as ETV6), encoding a protein of the ETS transcription factor family, is involved in various rearrangements of human malignancies.1 The partner genes identified to date can be classified into two main subtypes according to the function of their encoded product: gene encoding proteins with tyrosine kinase activity and gene encoding transcription factors. The situation is less clear in several uncommon chromosome translocations involving TEL, which do not result in obvious fusion product.2 They might sometimes result in the transcriptional activation of genes located in the vicinity of the breakpoint on the translocated chromosome partner, or in the partial inactivation of TEL.3 In most of the fusion proteins including TEL, the TEL moiety provides a strong oligomerization domain (SAM domain) or transcriptional repression properties.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Bohlander SK . Fusion genes in leukemia: an emerging network. Cytogenet Cell Genet 2000; 91: 52–56.

    Article  CAS  PubMed  Google Scholar 

  2. Poirel H, Lacronique V, Mauchauffé M, Le Coniat M, Raffoux E, Daniel M-T et al. Analysis of TEL proteins in human leukemias. Oncogene 1998; 16: 2895–2903.

    Article  CAS  PubMed  Google Scholar 

  3. Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I, Delforge M et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood 2002; 99: 1776–1784.

    Article  CAS  PubMed  Google Scholar 

  4. Buijs A, van Rompaey L, Molijn AC, Davis JN, Vertegaal AC, Potter MD et al. The MN1–TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol Cell Biol 2000; 20: 9281–9293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aarnoudse AJ, Hellemons A et al. The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR–RXR-mediated transcription. Oncogene 2003; 22: 699–709.

    Article  CAS  PubMed  Google Scholar 

  6. Oval J, Jones OW, Montoya M, Taetle R . Characterization of a factor-dependent acute leukemia cell line with translocation (3;3)(q21;q26). Blood 1990; 76: 1369–1374.

    CAS  PubMed  Google Scholar 

  7. Hu ZB, Ma W, Zaborski M, MacLeod R, Quentmeier H, Drexler HG . Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3. Leukemia 1996; 10: 1025–1040.

    CAS  PubMed  Google Scholar 

  8. Buijs A, Sherr S, van Baal S, van Bezouw S, van der Plas D, Geurts van Kessel A et al. Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Oncogene 1995; 10: 1511–1519.

    CAS  PubMed  Google Scholar 

  9. Ayton PM, Cleary ML . Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20: 5695–5707.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partly supported by the INSERM, the Ligue Nationale contre le Cancer (LNCC), the Comité de Paris de la Ligue Nationale Contre le Cancer (LNCC-CP), and the Fondation pour la Recherche Médicale (FRM).

Author information

Author notes

  1. L Guglielmi

    Present address: INSERM U454, Hôpital Arnaud de Villeneuve, 371 Av. du doyen Gaston Giraud, 34295, Montpellier, Cedex 5, France

Authors and Affiliations

  1. INSERM E210-IRNEM, Hôpital Necker, Paris, France

    V Della Valle, L Guglielmi, M Busson, R Berger & O A Bernard

  2. Department of Pathology, Josphine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands

    E C Zwarthoff

Authors
  1. V Della Valle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Guglielmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Busson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E C Zwarthoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O A Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O A Bernard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valle, V., Guglielmi, L., Busson, M. et al. Expression of the MN1–TEL fusion protein in the human UCSD/AML1 leukemic cell line. Leukemia 18, 1558–1560 (2004). https://doi.org/10.1038/sj.leu.2403420

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403420

Search

Advanced search

Quick links